MetaVia (MTVA) News Today $0.67 0.00 (-0.40%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesSEC FilingsTrendsBuy This Stock MTVA Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period MetaVia Inc.: MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum ...July 10, 2025 | finanznachrichten.deMetaVia doses first patient in 48 mg MAD cohort of its Phase 1 trialJuly 10, 2025 | msn.comMetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum Tolerated DoseJuly 9, 2025 | prnewswire.comOTC Markets Hosts Virtual Investor Presentation with HH Kim, President and CEO of MetaVia Inc., and David Bautz, PhD, Senior Analyst at Zacks SCRJune 27, 2025 | msn.comMTVA: DA-1241 in Combination with Efruxifermin Shows Additive Hepatoprotective Effects in Mouse MASH Model…June 24, 2025 | finance.yahoo.comMetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA's 85th Scientific SessionJune 21, 2025 | prnewswire.comMetaVia to Present at the Life Sciences Virtual Investor Forum June 12thJune 10, 2025 | financialpost.comFMetaVia to Present at the Life Sciences Virtual Investor Forum June 12thJune 10, 2025 | globenewswire.comMetaVia Announces Poster Presentation on DA-1241 at the ADA's 85th Scientific SessionsJune 4, 2025 | prnewswire.comMTVA stock touches 52-week low at $0.64 amid market challengesJune 1, 2025 | uk.investing.comMetaVia Faces Nasdaq Delisting Notice for Low Stock PriceMay 30, 2025 | tipranks.comMTVA: Additional Positive Topline Results for DA-1726 in Phase 1 MAD Study…May 22, 2025 | finance.yahoo.comMetaVia Updates Corporate Presentation on DA-1726 ProgressMay 21, 2025 | tipranks.comMetaVia Inc.: MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 20, 2025 | finanznachrichten.deMetaVia Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 14, 2025 | prnewswire.comMetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq RulesMay 9, 2025 | prnewswire.comMetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025May 7, 2025 | prnewswire.comMetaVia’s DA-1726 obesity candidate shows efficacy in Part 2 of Phase 1 studyApril 24, 2025 | markets.businessinsider.comMetaVia Advances Pipeline Targeting Obesity, Diabetes, and MASH; Phase 2a Data on DA-1241 to be Presented at EASL 2025April 23, 2025 | theglobeandmail.comMetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025April 23, 2025 | prnewswire.comMetaVia Reports Positive Phase 1 Trial ResultsApril 22, 2025 | tipranks.comMetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class PotentialApril 22, 2025 | prnewswire.comMetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing ...April 17, 2025 | seekingalpha.comMTVA: Positive Phase 1 MAD Data for DA-1726; Excellent Tolerability Profile and Mean Day 26 Weight Loss of 4.3%…April 17, 2025 | msn.comMetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and TolerabilityApril 15, 2025 | prnewswire.comMTVA: Phase 1 Part 2 Data for DA-1726 in Obesity Expected Soon…March 31, 2025 | finance.yahoo.comMetaVia Inc. Reports Progress in Cardiometabolic Drug DevelopmentMarch 21, 2025 | tipranks.comMetaVia Inc.: MetaVia Reports Year End 2024 Financial Results and Provides Corporate UpdateMarch 21, 2025 | finanznachrichten.deMetaVia Reports Year End 2024 Financial Results and Provides Corporate UpdateMarch 20, 2025 | prnewswire.comMetaVia Advances Therapeutics with Promising Trial UpdatesJanuary 10, 2025 | tipranks.comMetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 ConferenceJanuary 10, 2025 | prnewswire.comMetaVia initiated with a Buy at H.C. WainwrightDecember 31, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: MetaVia (MTVA), Century Therapeutics (IPSC)December 31, 2024 | markets.businessinsider.comMTVA: Compelling Data for DA-1241 in Phase 2a MASH Trial…December 21, 2024 | msn.comMerck-Hansoh deal for oral GLP-1 hurts obesity drug developersDecember 18, 2024 | msn.comMetaVia Announces Positive Phase 2a Clinical Data For DA-1241 In Patients With Presumed MASHDecember 18, 2024 | markets.businessinsider.com Get MetaVia News Delivered to You Automatically Sign up to receive the latest news and ratings for MTVA and its competitors with MarketBeat's FREE daily newsletter. Email Address MTVA Media Mentions By Week MTVA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MTVA News Sentiment▼-0.130.96▲Average Medical News Sentiment MTVA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MTVA Articles This Week▼11▲MTVA Articles Average Week Get MetaVia News Delivered to You Automatically Sign up to receive the latest news and ratings for MTVA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies APLT News IPSC News AVTX News KRON News ANVS News VTVT News ZIVO News ADVM News RENB News ALGS News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MTVA) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MetaVia Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MetaVia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MTVA Stock Alerts